WebDec 8, 2024 · Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). Increasingly, low-dose once-a … WebJan 6, 2024 · 1 INTRODUCTION. Head and neck cancer is the seventh most common cancer type worldwide. 1 Cure rates of patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) vary between 30% and 60%, and in case of metastases or local recurrence, palliative treatment is often the only option. 2 In this …
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck …
WebSep 18, 2024 · NCBI Bookshelf WebBackground: Triweekly high-dose cisplatin (100 mg/m 2) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC).We compared triweekly 100 mg/m 2 with alternative weekly 40 mg/m 2 and weekly <40 mg/m 2 cisplatin regimens.. Methods: … richard miller attorney binghamton
Failure of Alkylating Agents to Improve Induction Chemotherapy …
WebNov 15, 2024 · Cisplatin chemotherapy can bring lasting adverse health effects, but a new, presumably less-toxic alternative is not as effective at promoting survival, according to a … WebCisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, … Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein. Common side … See more Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some See more Cisplatin is the square planar coordination complex cis-[Pt(NH3)2Cl2]. The prefix cis indicates the cis isomer in which two similar ligands are in … See more Syntheses of cisplatin start from potassium tetrachloroplatinate. Several procedures are available. One obstacle is the facile formation of See more Cisplatin has been studied with Auger therapy to increase the therapeutic effects of cisplatin, without increasing normal tissue toxicities. See more Cisplatin has a number of side effects that can limit its use: • Nephrotoxicity (kidney damage) is the primary dose-limiting side effect and is of major clinical concern. Cisplatin selectively accumulates into the proximal tubule via basolateral-to … See more Cisplatin interferes with DNA replication, which kills the fastest proliferating cells, which in theory are cancerous. Following administration, one chloride ion is slowly displaced by water to give the aquo complex cis-[PtCl(NH3)2(H2O)] , in a process termed See more The compound cis-[Pt(NH3)2Cl2] was first described by Italian chemist Michele Peyrone in 1845, and known for a long time as Peyrone's salt. The structure was deduced by See more richard miller attorney albany ny